P
Pierre-Blaise Matsiegui
Researcher at Albert Schweitzer Hospital
Publications - 37
Citations - 1881
Pierre-Blaise Matsiegui is an academic researcher from Albert Schweitzer Hospital. The author has contributed to research in topics: Malaria & Population. The author has an hindex of 19, co-authored 35 publications receiving 1749 citations. Previous affiliations of Pierre-Blaise Matsiegui include University of Tübingen.
Papers
More filters
Journal ArticleDOI
Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial.
Martin Adjuik,Patrice Agnamey,Abdel Babiker,Steffen Borrmann,Steffen Borrmann,Philippe Brasseur,M. Cisse,Frank Cobelens,Diallo S,Jean-François Faucher,Paul Garner,S. Gikunda,Peter G. Kremsner,Peter G. Kremsner,Sanjeev Krishna,Sanjeev Krishna,Bertrand Lell,Bertrand Lell,M. Loolpapit,Pierre-Blaise Matsiegui,Michel A. Missinou,Michel A. Missinou,J. Mwanza,Francine Ntoumi,Piero Olliaro,P. Osimbo,Philipp Rezbach,Philipp Rezbach,Eliab Some,Walter R. J. Taylor +29 more
TL;DR: The combination of artesunate and amodiaquine improved treatment efficacy in Gabon and Kenya, and was equivalent in Sénégal, and is a potential combination for use in Africa.
Journal ArticleDOI
Fosmidomycin for malaria
Michel A. Missinou,Steffen Borrmann,Steffen Borrmann,Andreas Schindler,Andreas Schindler,Saadou Issifou,Saadou Issifou,Ayola A. Adegnika,Ayola A. Adegnika,Pierre-Blaise Matsiegui,Pierre-Blaise Matsiegui,Ronald K. Binder,Ronald K. Binder,Bertrand Lell,Bertrand Lell,Jochen Wiesner,Thomas Baranek,Hassan Jomaa,Peter G. Kremsner,Peter G. Kremsner +19 more
TL;DR: It is suggested that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more.
Journal ArticleDOI
Prevalence of Plasmodium falciparum infection in pregnant women in Gabon.
Marielle K. Bouyou-Akotet,Denisa E Ionete-Collard,Modeste Mabika-Manfoumbi,Eric Kendjo,Pierre-Blaise Matsiegui,Elie Mavoungou,Elie Mavoungou,Maryvonne Kombila +7 more
TL;DR: The prevalence of malaria and the prevalence of anaemia, whether associated with malaria or not, are higher in pregnant women in Gabon and it is urgent to design an effective regimen of malaria prophylaxis for this high risk population.
Journal ArticleDOI
Fosmidomycin-Clindamycin for the Treatment of Plasmodium falciparum Malaria
Steffen Borrmann,Steffen Borrmann,Saadou Issifou,Saadou Issifou,Gilbert Esser,Gilbert Esser,Ayola A. Adegnika,Ayola A. Adegnika,Michael Ramharter,Michael Ramharter,Pierre-Blaise Matsiegui,Pierre-Blaise Matsiegui,Sunny Oyakhirome,Denise P. Mawili Mboumba,Denise P. Mawili Mboumba,Michel A. Missinou,Michel A. Missinou,Jürgen F. J. Kun,Hassan Jomaa,Peter G. Kremsner,Peter G. Kremsner +20 more
TL;DR: Fosmidomycin-clindamycin is safe and well tolerated, and short-course regimens achieved high efficacy in children with P. falciparum malaria and is a promising novel treatment option for malaria.
Journal ArticleDOI
Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria
Steffen Borrmann,Steffen Borrmann,Steffen Borrmann,Ingrid Lundgren,Ingrid Lundgren,Sunny Oyakhirome,Bénido Impouma,Pierre-Blaise Matsiegui,Pierre-Blaise Matsiegui,Ayola A. Adegnika,Ayola A. Adegnika,Saadou Issifou,Saadou Issifou,Jürgen F. J. Kun,David Hutchinson,Jochen Wiesner,Hassan Jomaa,Peter G. Kremsner,Peter G. Kremsner +18 more
TL;DR: Efficacy appeared to be significantly reduced in children aged 1 to 2 years, with a day 28 cure rate of only 62% for this small subgroup, highlighting the need for continued systematic studies of the current dosing regimen, which should include randomized trial designs.